One year in review
One year in review 2018: systemic vasculitis
E. Elefante1, M. Bond2, S. Monti3, G. Lepri4, E. Cavallaro5, M. Felicetti6, E. Calabresi7, C. Posarelli8, R. Talarico9, L. Quartuccio10, C. Baldini11
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital 'Santa Maria della Misericordia', Udine, Italy
- Department of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
- Department of Clinical and Experimental Medicine, Division of Rheumatology, University of Florence, AOUC, Florence, Italy.
- Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital 'Santa Maria della Misericordia', Udine, Italy.
- Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Ophthalmology Unit, Department of Surgical, Medical, Molecular Pathology and Emergency, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital 'Santa Maria della Misericordia', Udine, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiara.baldini74@gmail.com
CER11381
2018 Vol.36, N°2 ,Suppl.111
PI 0012, PF 0032
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 29799395 [PubMed]
Received: 06/05/2018
Accepted : 07/05/2018
In Press: 18/05/2018
Published: 18/05/2018
Abstract
Systemic vasculitis are heterogeneous, complex and disabling disorders. Following the previous annual reviews of this series, this paper gives a brief overview on current knowledge about recent literature on small- and large-vessel systemic vasculitis, with a specific focus on pathogenetic and clinical aspects, novel possible disease-related biomarkers and current and future therapies that are in the pipeline.